Injectable Drug Delivery: Market Impact and Industry Trends

Injectable Drug Delivery: Market Impact and Industry Trends

As competition in the pharmaceutical marketplace grows, companies are increasingly looking towards the drug delivery industry to maximize revenues and combat generic competitors. The search for more efficient drug delivery systems is also being driven by the rise in patient demand, healthcare and pharma cost containment, as much as by medical and technological advances.

The global market for drug delivery technology is worth in excess of US$25 billion in sales. Given its predicted annual growth of 15 percent, the market represents a considerable business opportunity, which has been reflected in the increasing number of drug delivery specialists. According to The author; new report entitled Injectable Drug Delivery: Market Impact and Industry Trends, injectables currently account for an estimated 15 percent of the global drug delivery market, with the US being the leading individual market.

Key features of this report:

• Overview of the drug delivery environment
• In-depth analysis of the injectable drug delivery industry, including main types and main marketed systems, and their advantages and disadvantages
• Comprehensive facts and figures for the injectable drug delivery market, including main players and key therapeutic areas
• Future trends in the injectables marketplace, shaped by medical and technological advances as much as demographic and epidemiological changes and industry needs
• Outlook for the injectable drug delivery technology

• Stakeholders in the injectable drug delivery market
• Companies interested in understanding the impact and implications of securing the correct injectable drug delivery technology in terms of product placement, lifecycle management and competition in the marketplace
• Companies interested in understanding future opportunities in the injectable drug delivery sector provided by a combination of factors, including changing public health needs
• Pharma/biotech companies wishing to identify potential injectable drug delivery areas for partnerships and collaboration in order to examine a variety of profit maximization strategies

1. Executive Summary

2. Introduction to Drug Delivery
2.1. Drug Delivery Technologies and Pharmaceutical Revenues
2.2. Drug Delivery Technologies and Wider Healthcare Market
3. Overview of Injectable Drug Delivery
3.1. Advantages and Disadvantages of Injectable Delivery
3.2. Types of Injectable Drug Delivery

4. Main Categories of Marketed Injectable Drug Delivery Systems
4.1. Sustained Release Injectable Systems
4.2. Advantages of Injectable Sustained-Release Formulations
4.3. Liposomal Systems
4.4. Advantages of Injectable Liposomal Formulations
4.5. Needleless Systems
4.6. Advantages of Injectable Needleless Formulations

5. Injectable Drug Delivery Market – Facts and Figures
5.1. Injectable Drug Delivery Market Overview
5.2. Key Therapeutic Areas for Injectable Drug Delivery
5.3. Acromegaly
5.4. Age-Related Macular Degeneration
5.5. Crohn’s Disease
5.6. Diabetes
5.7. Hepatitis C
5.8. Multiple Sclerosis
5.9. Neutropenia
5.10. Oncology
5.11. Pain
5.12. Psoriasis
5.13. Rheumatoid Arthritis

6. Drug Classes Appropriate for Injectable Drug Delivery

7. Main Players and Partnerships in the Injectable Drug Delivery Market

8. Key Company Involvement in the Field of Injectable Drug Delivery
8.1. Alkermes
8.2. ALZA
8.3. Aradigm
8.4. Bioject
8.5. Enzon
8.6. Ethypharm
8.7. MacroMed
8.8. Nektar Therapeutics
8.9. QLT
8.10. SkyePharma

9. Sales of Products Utilizing Injectable Drug Delivery Technology
10. Profiles of Key Products Using Injectable Drug Delivery Technology
10.1. Neulasta (Nektar/Amgen)
10.2. PEGASYS (Roche/Nektar)
10.3. PEG-Intron (Schering-Plough)
10.4. Risperdal Consta
10.5. Sandostatin (Novartis)
10.6. Vivitrol (Alkermes)

11. Recent Launches and Approvals in the Field of Injectable Drug Delivery
11.1. August 2006
11.2. July 2006
11.3. May 2006
11.4. April 2006
11.5. February 2006
11.6. January 2006

12. Current Research and Profiles of Key Pipeline Products in the Field of Injectable Drug
Delivery
12.1. Cimzia (Nektar)
12.2. Mircera/CERA (Nektar)
12.3. Paliperidone Palmitate (Johnson & Johnson)
12.4. Intraject Sumatriptan (Zogenix)

13. Future of Injectable Drug Delivery Technology
13.1. Emerging Injectable Drug Delivery Technologies
13.2. Emerging Therapeutic Targets for Injectable Drug Delivery
13.3. Future Therapeutic Targets for Injectable Drug Delivery
13.4. New Technology and the Injectable Drug Delivery Market
13.5. New Threats to the Injectable Drug Delivery Market
13.6. New Healthcare Needs and the Injectable Drug Delivery

14. Outlook for Injectable Drug Delivery Technology

List of Tables

Table 2.1 Drivers of New Drug Delivery Technologies
Table 2.2 Advantages of New Drug Delivery Technology
Table 3.1 Types of Injectable Delivery
Table 4.1 Key Companies in the Needleless Drug Technology Market
Table 5.1 Leading MS Therapy Delivery Routes and Dosage
Table 5.2 Key Biologics for the Treatment of Psoriasis
Table 5.3 Administration Methods of Main RA Therapies
Table 7.1 Leading Injectable Drug Delivery Companies 2005, Key Products and Sales 2005 ($ mn)
Table 7.2 Novartis’ Pipeline Major Drug Delivery Partners
Table 8.1 Key Details of Main Companies in the Field of Injectable Drug Delivery
Table 8.2 Alkermes’ Injectable Drug Delivery Portfolio, 2006
Table 8.3 Bioject’s Injectable Drug Delivery Portfolio, 2006
Table 8.4 Enzon’s Injectable Drug Delivery Portfolio, 2006
Table 8.5 Ethypharm’s Injectable Drug Delivery Portfolio, 2006
Table 8.6 MacroMed’s Injectable Drug Delivery Portfolio, 2006
Table 8.7 Nektar’s Injectable Drug Delivery Portfolio, 2006
Table 8.8 SkyePharma’s Injectable Drug Delivery Portfolio, 2006
Table 9.1 Key Injectable Drug Delivery Products, 2004-2005 ($ mn)
Table 10.1 GH Suppression During Long-Term Treatment with Immediate Release Sandostatin Injection and
Sandostatin LAR Depot
Table 10.2 Comparison of Acromegaly Symptoms with Immediate Release Sandostatin Injection and Sandostatin
LAR Depot as Reported by Patients
Table 13.1 Key Injectable Drug Delivery R&D Pipeline Drugs, 2006
Table 13.2 Other Viral and Bacterial Infections to Which Injectable Technology is Applicable
Table 13.3 Emerging Therapeutic Areas for Injectable Drug Delivery
Table 13.4 DOR BioPharma Drug Delivery Portfolio, 2006
Table 14.1 Drivers and Restraints of Injectable Drug Delivery

List of Graphs
Graph 5.1 2005 Sales of Leading MS Therapies
Graph 5.2 2005 Sales of Leading Psoriasis Biologics
Graph 5.3 2005 Sales of Leading RA Therapies
Graph 7.1 Leading Injectable Drug Delivery Companies, Combined Key Product Values 2005 ($ mn)
Graph 7.2 Leading Companies Active in Injectable Drug Delivery Development, Number of Products
Graph 9.1 Top Ten Products Utilizing Injectable Delivery, Global Sales 2005 ($ mn)

List of Figures
Figure 4.1 Patient Perception of Iject and Associated Pain
Figure 8.1 Illustration of ALZAMER’s PLGA Solvent Control over Protein Release
Figure 8.2 Advanced PEGylated Drug Molecules
Figure 8.3 Four Stages of Photodynamic Therapy
Figure 12.1 Illustration of NanoCrystal Dispersion’s Advantages
Figure 13.1 Comparison of Morphine Delivery Technologies: Oral, Injectable and Transmucosal

Diagrams
Diagram 4.1 Rheumatoid Arthritis Treatment Guidelines
Diagram 4.2 The American College of Rheumatology Criteria (ACR) Criteria